Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetes Care

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.28.10.2345PMID 16186261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005cited by this paper
• Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.

  2004cited by this paper
• Observational Studies of Treatment Effectiveness: Some Cautions

  2004cited by this paper
• The phantom of lactic acidosis due to metformin in patients with diabetes.

  2004cited by this paper
• Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

  2004cited by this paper
• The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.

  2004cited by this paper
• Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus

  2004cited by this paper
• Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk

  2004cited by this paper
• Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes.

  2004influential reference
• Impact of diabetes mellitus on long-term survival in patients with congestive heart failure.

  2004cited by this paper
• Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study

  2004cited by this paper
• Metformin and lactic acidosis: cause or coincidence? A review of case reports

  2004cited by this paper
• Metformin and thiazolidinedione use in Medicare patients with heart failure.

  2003cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2003cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Frequency of inappropriate metformin prescriptions.

  2002cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2002cited by this paper
• When are medication side effects due to the nocebo phenomenon

  2002cited by this paper
• The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

  2002cited by this paper
• Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

  2001cited by this paper
• Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project.

  2000cited by this paper
• Low-dose inhaled corticosteroids and the prevention of death from asthma.

  2000cited by this paper
• Use of comorbidity scores for control of confounding in studies using administrative databases.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Contra‐indications to metformin therapy are largely disregarded

  1999cited by this paper
• Lactic Acidosis in Metformin-Treated Patients

  1999cited by this paper
• Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.

  1999cited by this paper
• Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Estimating Causal Effects from Large Data Sets Using Propensity Scores

  1997cited by this paper
• The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes

  1996cited by this paper
• Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

  1996cited by this paper
• 3 The Cochrane Library

  1996cited by this paper
• U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

  1995cited by this paper
• A Chronic Disease Score with Empirically Derived Weights

  1995cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Replicating the chronic disease score (CDS) from automated pharmacy data.

  1994cited by this paper
• AHFS Drug Information

  1994cited by this paper
• The use of beta-agonists and the risk of death and near death from asthma.

  1992cited by this paper
• The use of beta-agonists and the risk of death and near death from asthma

  1992cited by this paper
• The Use of β-Agonists and the Risk of Death and near Death from Asthma

  1992cited by this paper
• A chronic disease score from automated pharmacy data.

  1992cited by this paper
• The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy.

  1975cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

  1970cited by this paper

• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view.

  2025cites this paper
• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome.

  2025cites this paper
• Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

  2024influential citation
• Preadmission metformin use increased the incidence of hyperlactatemia at admission and 30-day in-hospital mortality among T2D patients with heart disease at high risk of hypoxia.

  2024cites this paper
• Eurasian Association of Cardiology (EAC)/ National Society of Heart Failure And Myocardial Disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2024)

  2024cites this paper
• Exploring the link between metformin use and adhesive capsulitis of the shoulder: a retrospective cohort study in Taiwan

  2024cites this paper
• A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)

  2024cites this paper
• Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis

  2024cites this paper
• The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity.

  2024cites this paper
• A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd Edition (English version)

  2024cites this paper
• 2024 Clinical practice guidelines for Chronic heart failure

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• Metformin treatment is associated with improved survival in diabetic patients hospitalized with acute heart failure: A prospective observational study using the Korean Acute Heart Failure registry data.

  2023cites this paper
• The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy

  2023cites this paper
• Prognostic impact of metformin in patients with type 2 diabetes mellitus and acute heart failure: Combined analysis of the EAHFE and RICA registries.

  2023cites this paper
• Documento de consenso sobre el manejo de la diabetes tipo 2 y la insuficiencia cardíaca: Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC)

  2023cites this paper
• Diabetestherapie bei herzkranken Patienten

  2023cites this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cites this paper
• Impacto pronóstico de metformina en pacientes con diabetes mellitus tipo 2 e insuficiencia cardiaca aguda. Análisis combinado de los registros EAHFE y RICA

  2023cites this paper
• Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort

  2023cites this paper
• Применение метформина у больных сахарным диабетом 2 типа при остром инфаркте миокарда: безопасность и влияние на гликемический контроль

  2023cites this paper
• Treatment of type 2 diabetes patients with heart conditions

  2023cites this paper
• Diabetestherapie bei herzkranken Patienten

  2023cites this paper
• A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes

  2022cites this paper
• Metformin: new applications for an old drug

  2022cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.

  2022cites this paper
• A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

  2022cites this paper
• Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)

  2022cites this paper
• HbA1c level is associated with the development of heart failure with recovered ejection fraction in hospitalized heart failure patients with type 2 diabetes.

  2022cites this paper
• Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction

  2022cites this paper
• Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal

  2022cites this paper
• Positionspapier Herzinsuffizienz und Diabetes

  2022cites this paper
• Myeloid differential protein-2 inhibition improves diabetic cardiomyopathy via p38MAPK inhibition and AMPK pathway activation.

  2022cites this paper
• Die Kardiologie

  2022cites this paper
• Clinical Practice Guideline for the management of Type 2 Diabetes Mellitus in patients with Heart Failure at Daniel Alcides Carrion National Hospital (Callao, Peru)

  2022cites this paper
• Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases

  2022cites this paper
• Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies.

  2022cites this paper
• ЕВРАЗИЙСКИЕ РЕКОМЕНДАЦИИ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ДИАБЕТОМ И ПРЕДИАБЕТОМ (2021)

  2021cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Lactate and Myocardiac Energy Metabolism

  2021cites this paper
• Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence

  2021cites this paper
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.

  2021cites this paper
• CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.

  2021cites this paper
• Diabetes Mellitus

  2021cites this paper
• Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?

  2021cites this paper
• Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy.

  2021cites this paper
• [Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].

  2021cites this paper
• Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

  2021cites this paper
• Diabetes Management in Patients with Heart Failure

  2021cites this paper
• Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.

  2021cites this paper
• EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)

  2021cites this paper
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.

  2021cites this paper
• The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

  2021cites this paper
• Metformin in patients with type 2 diabetes mellitus and heart failure: a review.

  2021cites this paper
• Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?

  2020cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• Evolution of Myocardial Dysfunction in Asymptomatic Patients at Risk of Heart Failure.

  2020cites this paper
• DMSO_A_237454 2093..2108

  2020cites this paper
• Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes　- A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society.

  2020cites this paper
• Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

  2020cites this paper
• Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Metformin in Patients with Chronic Heart Failure

  2020cites this paper
• Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society

  2020cites this paper
• Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?

  2020cites this paper
• EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020)

  2020cites this paper
• Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments.

  2020cites this paper
• Influence of environment variations on anti-glycaemic, anti-cholesterolemic, antioxidant and antimicrobial activities of natural wild fruits of Ziziphus lotus (L.).

  2020cites this paper
• Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus.

  2020cites this paper
• Chronic heart failure and diabetes mellitus: two unsuitably matched partners

  2020cites this paper
• Хроническая сердечная недостаточность. Клинические рекомендации 2020

  2020cites this paper
• Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels?

  2020cites this paper
• Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis

  2020cites this paper
• Diabetes mellitus type 2 in adults

  2020cites this paper
• Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

  2020cites this paper
• Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future

  2020cites this paper
• Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Complex management in diabetic patients with cardiovascular disease

  2020cites this paper
• Positioning Metabolism as a Central Player in the Diabetic Heart

  2020cites this paper
• Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors

  2019cites this paper
• The right place for Metformin today.

  2019cites this paper
• Do Drugs That Ameliorate Epicardial Adipose Tissue Inflammation Have Concordant Benefits on Atrial Fibrillation and on Heart Failure with a Preserved Ejection Fraction?

  2019cites this paper
• A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.

  2019cites this paper
• Heart failure and its complications in patients with diabetes: Mounting evidence for a growing burden

  2019cites this paper
• Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).

  2019cites this paper
• Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers

  2019cites this paper
• Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.

  2019cites this paper
• 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

  2019cites this paper
• Mitochondrial targets of metformin—Are they physiologically relevant?

  2019cites this paper
• Lactic Acidosis

  2019cites this paper
• Effects of sodium glucose cotransporter type 2 inhibitors on heart failure

  2019cites this paper
• Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm.

  2019cites this paper
• New advances in perioperative cardioprotection

  2019cites this paper
• Mechanisms of action of metformin with special reference to cardiovascular protection

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors.

  2019cites this paper